17.17

2.28% -0.40

Pre-market: 17.29 0.12 +0.70%

Day One Biopharmaceuticals Inc (DAWN)

Overview News Price History Option Chain Financials Discussions Forecast

Day One Biopharmaceuticals Inc stock is currently priced at $17.17, with a 24-hour trading volume of 1.16M. It has seen a -2.28% decreased in the last 24 hours and a +10.06% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $17.52 pivot point. If it approaches the $17.10 support level, significant changes may occur.

Previous Close:

$17.57

Open:

$18

24h Volume:

1.16M

Market Cap:

$1.50B

Revenue:

Net Income/Loss:

$-188.92M

P/E Ratio:

-7.4652

EPS:

-2.3

Net Cash Flow:

$-150.08M

1W Performance:

+15.08%

1M Performance:

+10.06%

6M Performance:

+34.56%

1Y Performance:

+20.83%

1D Range:

$17.13

$18.00

52W Range:

$9.67

$18.07

Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile

Name

Day One Biopharmaceuticals Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

650 484 0899

Address

395 Oyster Point Boulevard, Suite 217, South San Francisco

Employee

Twitter

Next Earnings Date

Latest SEC Filings

DAWN's Discussions on Twitter

Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-25-23	Downgrade	BofA Securities	Buy → Underperform
Feb-08-23	Initiated	CapitalOne	Overweight
Feb-03-23	Initiated	Oppenheimer	Perform
Dec-15-22	Initiated	H.C. Wainwright	Buy
Dec-14-22	Initiated	Needham	Buy
Dec-05-22	Initiated	Goldman	Buy
Dec-01-22	Initiated	BofA Securities	Buy

View All

Day One Biopharmaceuticals Inc Stock (DAWN) Latest News

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

GlobeNewswire Inc.

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

GlobeNewswire Inc.

Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data

Day One Biopharmaceuticals Inc (DAWN) Net Income 2024

DAWN net income (TTM) was -$188.92 million for the quarter ending December 31, 2023, a -32.87% decrease year-over-year.

Day One Biopharmaceuticals Inc (DAWN) Cash Flow 2024

DAWN recorded a free cash flow (TTM) of -$150.08 million for the quarter ending December 31, 2023, a -36.56% decrease year-over-year.

Day One Biopharmaceuticals Inc (DAWN) Earnings per Share 2024

DAWN earnings per share (TTM) was -$2.38 for the quarter ending December 31, 2023, a -9.68% decline year-over-year.

Day One Biopharmaceuticals Inc Stock (DAWN) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
York Charles N II	COO, CFO AND SECRETARY	May 03 '24	Sale	17.85	8,078	144,214	217,293
York Charles N II	COO, CFO AND SECRETARY	May 02 '24	Sale	17.90	200	3,579	225,371
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 02 '24	Sale	17.94	6	108	651,756
Bender Jeremy	CHIEF EXECUTIVE OFFICER	May 01 '24	Sale	17.88	70,051	1,252,183	651,762
York Charles N II	COO, CFO AND SECRETARY	May 01 '24	Sale	17.89	52,183	933,397	225,571
Blackman Samuel C.	HEAD OF R&D	Apr 18 '24	Sale	16.02	10,000	160,163	1,174,662
Blackman Samuel C.	HEAD OF R&D	Mar 25 '24	Sale	16.01	10,000	160,055	1,184,662
Blackman Samuel C.	HEAD OF R&D	Mar 11 '24	Sale	15.24	30,000	457,314	1,194,662
Blackman Samuel C.	HEAD OF R&D	Feb 27 '24	Sale	16.11	20,000	322,166	1,224,662
Bender Jeremy	CHIEF EXECUTIVE OFFICER	Feb 16 '24	Sale	15.25	7,615	116,114	721,813

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.